BBNX
Beta Bionics, Inc. Common Stock
NASDAQ: BBNX · HEALTHCARE · MEDICAL DEVICES
$9.85
+0.00% today
Updated 2026-06-05
Market cap
$540.09M
P/E ratio
—
P/S ratio
4.90x
EPS (TTM)
$-1.37
Dividend yield
—
52W range
$9 – $33
Volume
1.0M
WallStSmart proprietary scores
38
out of 100
Grade: D
Sell
Investment rating
6.3
Growth
B7.8
Quality
B+2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$19.18
+94.72%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy7 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 56.60% QoQ
+ Debt/equity 0.03x — low leverage
Risks
- Thin margins at -60.30%
- Negative free cash flow $-25.21M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $179000.00 | $11.99M | $65.12M | $100.25M | $110.24M |
| Net income | $-64.75M | $-44.10M | $-54.76M | $-73.20M | $-21.89M |
| EPS | — | — | — | — | $-1.37 |
| Free cash flow | $-60.98M | $-32.85M | $-51.67M | $-56.22M | $-25.21M |
| Profit margin | -36,173.74% | -367.64% | -84.08% | -73.02% | -60.30% |
Peer comparison
Smart narrative
Beta Bionics, Inc. Common Stock trades at $9.85. Our Smart Value Score of 38/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. TTM revenue stands at $110.24M. with profit margins at -60.30%.
Frequently asked questions
What is Beta Bionics, Inc. Common Stock's stock price?
Beta Bionics, Inc. Common Stock (BBNX) trades at $9.85, on a P/S of 4.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Beta Bionics, Inc. Common Stock overvalued?
Beta Bionics, Inc. Common Stock carries a Smart Value Score of 38/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Beta Bionics, Inc. Common Stock (BBNX)?
The 12-month analyst consensus target is $19.18, about 94.7% above the current $9.85. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Beta Bionics, Inc. Common Stock's revenue?
Beta Bionics, Inc. Common Stock's trailing twelve-month revenue is $110.24M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.90x
ROE-24.49%
Beta—
50D MA$10.69
200D MA$18.72
Shares out0.04B
Float0.03B
Short ratio—
Avg volume1.0M
Performance
1 week+0.00%
1 month+50.98%
3 months+33.69%
YTD-54.41%
1 year—
3 years—
5 years—